ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Santhera, Cold Spring Harbor Lab to Investigate Lonodelestat in COVID-19-related ARDS
April 30, 2020Santhera Pharmaceuticals has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE). -
Santhera explores lonodelestat to treat ARDS in Covid-19 patients
April 30, 2020Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19. -
Santhera, CSHL to Investigate Lonodelestat in COVID-19-related ARDS
April 28, 2020Lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), has potential as a therapeutic intervention for COVID-19-related ARDS.
Pharma Sources Insight January 2025
